Poliomyelitis: all 227 studies
Page 2 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021CompletedNCT04939350
- Clinical Trial of Novel OPV2 VaccineCompletedNCT04693286Phase 2
- Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine ImmunizationCompletedNCT04618783Not applicable
- To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 YearsStatus unknownNCT04618640Phase 3
- A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in ChinaCompletedNCT04614597
- Immunogenicity nOPV2 With and Without bOPVCompletedNCT04579510Phase 2
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in ChinaCompletedNCT04576910Phase 4
- Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)CompletedNCT04448132Phase 4
- Effect of Lactoferrin on Polio SeroconversionCompletedNCT04432935Not applicable
- Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio VaccineCompletedNCT04386707Phase 3
- Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin StrainCompletedNCT04224519Phase 4
- Inactivated Poliomyelitis Vaccine Made From Sabin StrainCompletedNCT04220515Phase 4
- Effect of Ankle-foot Orthoses on Balance ConfidenceCompletedNCT04080687
- Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsStatus unknownNCT04073459Phase 2
- Immunogenicity of Intramuscular and Intradermal IPVTerminatedNCT04063150Phase 4
- Treatment of Post-poliomyelitis Syndrome by Intravenous ImmunoglobulinCompletedNCT04004390
- Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) AdjuvantCompletedNCT03922061Phase 1
- Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in BangladeshStatus unknownNCT03890497Phase 4
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in InfantsCompletedNCT03822767Phase 3
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in InfantsCompletedNCT03822754Phase 3
- Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus VaccineStatus unknownNCT03821441Phase 3
- Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array CardStatus unknownNCT03818477
- Persistence of IPV ImmunityCompletedNCT03723837Phase 4
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity StudyCompletedNCT03722004Phase 4
- Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 MonthsCompletedNCT03671616Phase 3
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPVCompletedNCT03614702Phase 3
- A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.CompletedNCT03597919Phase 4
- Spinal Cord Gray Matter Imaging in Post Polio SyndromeStatus unknownNCT03561623
- Sero-conversion Study for a Two-dose Schedule of Sabin IPV in ChinaCompletedNCT03546634Phase 4
- An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old InfantsCompletedNCT03526978Phase 3
- Characterization of the Immunological Profile Patients With Post-polio SyndromeCompletedNCT03396783Not applicable
- Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCICompletedNCT03368885Not applicable
- Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in PakistanStatus unknownNCT03286803Phase 4
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsCompletedNCT03208101Phase 1
- Duration of IPV Priming and Antibody DecayCompletedNCT03202719Phase 4
- A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy InfantsCompletedNCT03169725Phase 2/3
- Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian InfantsWithdrawnNCT03128489Phase 3
- Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio PatientsCompletedNCT03064711Not applicable
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 MonthsCompletedNCT03032419Phase 3
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of AgeCompletedNCT03025750Phase 3
- A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio VaccineWithdrawnNCT03016949Phase 3
- Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus VaccineCompletedNCT02985320Phase 1/2
- A Campaign-based ID fIPV Administration TrialCompletedNCT02967783Not applicable
- Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus StudyCompletedNCT02847026Phase 4
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompletedNCT02817451Phase 3
- L-Citrulline in Patients With Post-Polio SyndromeCompletedNCT02801071Phase 3
- Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus VaccineCompletedNCT02785705Phase 3
- Safety and Immunogenicity of IPOVAC in Young ChildrenCompletedNCT02775942Phase 2
- A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven BiologicalsCompletedNCT02766816Phase 3
- Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio VaccineCompletedNCT02643446
- Immunogenicity of Monovalent Type 2 Oral Poliovirus VaccineCompletedNCT02643368Phase 4
- Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSCompletedNCT02458183Phase 3
- Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedNCT02428491Phase 3
- Intestinal and Humoral Immunity of Sequential Polio Vaccination SchedulesCompletedNCT02412514Phase 4
- 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to InfantsCompletedNCT02347423Phase 2
- Immunogenicity of Intramuscular Inactivated Poliovirus VaccineCompletedNCT02291263Phase 3
- DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsCompletedNCT02274285Phase 3
- The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)CompletedNCT02231632Phase 2/3
- Polio End-game Strategies - Poliovirus Type 2 Challenge StudyCompletedNCT02189811Phase 4
- DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsCompletedNCT02094833Phase 3
- Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control OrthosisActive, not recruitingNCT02089880Not applicable
- Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated PoliomyelitisCompletedNCT02040636Phase 2
- Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy AdultsCompletedNCT01997632Phase 1
- Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationCompletedNCT01983540Phase 3
- To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in PakistanStatus unknownNCT01908114Phase 4
- Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans NewbornsStatus unknownNCT01870206Phase 3
- IPV Clinical Trial - The GambiaCompletedNCT01847872Phase 4
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV VaccineStatus unknownNCT01841671Phase 4
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV VaccineCompletedNCT01831050Phase 4
- Immunogenicity of Inactivated and Live Polio VaccinesCompletedNCT01813604Phase 3
- Extramembranous and Interosseous Technique of Tibialis Posterior Tendon TransferTerminatedNCT01751503Not applicable
- Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in InfantsCompletedNCT01709071Phase 1/2
- Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy AdultsCompletedNCT01708720Phase 1
- Polio NID and Routine EPI Integration Trial PakistanCompletedNCT01697280Not applicable
- IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.CompletedNCT01695798Phase 4
- Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3CompletedNCT01586572Not applicable
- Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in BangladeshCompletedNCT01579825Not applicable
- Quality of Life in Adult Neurological PatientsCompletedNCT01573936Not applicable
- Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)CompletedNCT01571505Phase 1
- Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in KoreaCompletedNCT01568060
- Diarrhea and Bivalent Oral Polio Vaccine ImmunityCompletedNCT01559636Not applicable
- Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRECompletedNCT01546909Phase 4
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)CompletedNCT01510366Phase 3
- Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis VaccineCompletedNCT01475539Phase 4
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineCompletedNCT01457560Phase 3
- Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CourseCompletedNCT01457547Phase 4
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyCompletedNCT01457508Phase 3
- Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyCompletedNCT01457495Phase 2
- Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in JapanCompletedNCT01389687Phase 3
- Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or OlderCompletedNCT01287949Phase 3
- A Safety Study of IMOVAX Polio Vaccine in Selected Cities in ChinaCompletedNCT01278433Phase 4
- Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years OldCompletedNCT01249183Phase 3
- A Study of the Safety of IMOVAX Polio™ in ChinaCompletedNCT01244464Phase 4
- Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in PakistanCompletedNCT01229579Not applicable
- Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.CompletedNCT01214889Phase 3
- Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control VaccineCompletedNCT01105559
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)CompletedNCT01056705Phase 2
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin StrainsCompletedNCT01048190Phase 1
- Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of AgeCompletedNCT01031303Phase 4
- Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose IntramuscularlyCompletedNCT00885157Phase 2